Latest News and Press Releases

WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and...

- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201- Clinically meaningful tumor...

- Led by existing investors RA Capital Management and Boxer Capital- Purchase price of $17.50 represents a premium of approximately 44% to last close- Further strengthens balance sheet with pro forma...

iTeos Therapeutics Presents Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020 – Initial data from the dose escalation portion of the Phase 1/2a trial in 21...

            iTeos Therapeutics to Present Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020              Gosselies, Belgium and Cambridge, MA – April 20,...

iTeos Therapeutics to Present at Cowen 40th Annual Health Care Conference Cambridge, MA  and Gosselies, Belgium – February 24, 2020 – iTeos Therapeutics SA, a privately-held biotechnology company...

iTeos Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference Cambridge, MA  and Gosselies, Belgium – November 26, 2019 – iTeos Therapeutics SA, a privately-held biotechnology...

iTeos Therapeutics Announces Appointment of Matthew Call as Chief Operating Officer Gosselies, Belgium and Cambridge, MA – 13 August, 2019 – iTeos Therapeutics SA, a privately-held biotechnology...

iTeos Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference Gosselies, Belgium and Cambridge, MA – August 7, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company...

            iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019              Gosselies, Belgium and...